

# Ascendis Pharma Reports Third Quarter 2024 Financial Results

## November 14, 2024 at 4:01 PM EST

- YORVIPATH launching in U.S. with product availability expected mid-January 2025; ex-U.S. YORVIPATH revenue of €8.5 million in Q3

- TransCon CNP NDA submission for achondroplasia planned for Q1 2025 followed by MAA submission planned for Q3 2025
- SKYTROFA Q3 revenue of €47.2 million 60%+ year-over-year volume growth offset by current and prior period sales deductions

- Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be  $\in$  200 -  $\in$  220 million, and full year 2024 operating expenses of approximately  $\in$  600 million

- Novo Nordisk collaboration for the development of product candidates in metabolic and cardiovascular diseases, including a once-monthly GLP-1 receptor agonist, signed last week, seeking to close before the end of 2024

- Conference call today at 4:30 pm ET

COPENHAGEN, Denmark, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced financial results for the third quarter ended September 30, 2024, and provided a business update.

"2024 has been another transformative year for Ascendis. Now, all three of our three endocrinology rare disease programs have delivered clinically differentiated pivotal data, each demonstrating potential ability to address major unmet medical needs and the potential for each to achieve blockbuster status. We are ready and very excited about launching YORVIPATH in the U.S. with product availability expected in mid-January of 2025," said Jan Mikkelsen, Ascendis Pharma's President and Chief Executive Officer. "In addition, our new partnership with Novo Nordisk highlights our ability to extend the success of our TransCon platform and positions Ascendis to benefit patients and capture significant value in this large, high volume therapeutic areas."

## Select Highlights & Anticipated 2024 Milestones

• TransCon hGH:

(lonapegsomatropin, marketed as SKYTROFA)

- SKYTROFA revenue for the third quarter of 2024 totaled €47.2 million compared to €47.0 million during the same period in 2023. Volume growth was offset by higher sales deductions and a negative adjustment to prior period sales deductions of €2.5 million.
- SKYTROFA revenue for the first nine months of 2024 totaled €138.5 million, a 21% year-over-year increase compared to €114.4 million during the same period of 2023. Volume growth was partially offset by higher sales deductions. In addition, sales deductions attributable to periods prior to January 1, 2024 totaled €9.3 million.
- Submitted U.S. Food & Drug Administration (FDA) supplemental Biologics License Application for TransCon hGH for the treatment of adults with growth hormone deficiency.
- Topline results from Phase 2 New InsiGHTS Trial in Turner syndrome expected in the fourth quarter of 2024.
- Expect to initiate a basket trial evaluating SKYTROFA in other established daily growth hormone indications in the first half of 2025.

## TransCon PTH:

(palopegteriparatide, marketed as YORVIPATH)

- YORVIPATH launching in U.S. with our expanded U.S. field teams engaging with health care providers, our Ascendis Signature Access Program accepting prescriptions and enrolling patients starting in December in preparation for product availability in mid-January 2025
- Third quarter YORVIPATH revenue outside the U.S. totaled €8.5 million, a sequential quarter-over-quarter revenue increase of more than 60%, reflecting growing physician and patient demand with now over 600 patients on treatment, partially offset by accruals reflecting the end of the free pricing period in the third quarter. Final pricing in Germany is expected to be completed next year.

TransCon CNP

(navepegritide)

• Announced positive topline data from pivotal ApproaCH Trial with children with achondroplasia (ages 2-11 years)

treated with once-weekly TransCon CNP.

- Plan to submit New Drug Application (NDA) to the FDA for TransCon CNP for the treatment of children with achondroplasia during the first quarter of 2025 and a Marketing Authorisation Application (MAA) for the treatment of children with achondroplasia to the European Medicines Agency during the third quarter of 2025.
- Expect topline Week 26 data from COACH, the combination TransCon hGH and TransCon CNP trial of children with achondroplasia (ages 2-11 years) in the second quarter of 2025.
- Oncology Programs
  - Presented first results from platinum-resistant ovarian cancer (PROC) cohort of the Phase 1/2 IL-Believe Trial at ESMO 2024. Initial data suggest clinical activity in heavily pre-treated PROC patients and that TransCon IL-2 β/γ in combination with chemotherapy was generally well-tolerated.
  - Recently, we closed enrollment to dose expansion cohorts involving TransCon TLR7/8 Agonist in the transcendIT-101 and IL Believe trials to prioritize our efforts on TransCon IL-2 β/γ.
- Strategic Collaboration
  - In November, granted Novo Nordisk A/S an exclusive, multi-product, worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases and a product-by-product exclusive license in cardiovascular diseases. The lead program in the collaboration is a once-monthly GLP-1 receptor agonist product candidate that will initially target obesity and type 2 diabetes.
  - For the lead program, Ascendis will be eligible to receive total payments of up to \$285 million in upfront, development, and regulatory milestone payments, plus sales-based milestone payments and escalating tiered, mid-single digit royalties on global net sales.
  - Novo Nordisk will be responsible for Ascendis' early development costs as well as for clinical development, regulatory, commercial manufacturing, and commercialization activities.
- Financial Update and Outlook Based on Current Plans
  - As of September 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities, totaling €626 million, compared to €399 million as of December 31, 2023.
  - Full year 2024 SKYTROFA revenue excluding sales deductions related to prior years expected to be €200 €220 million.
  - Expect total operating expenses (SG&A and R&D) to be approximately €600 million for 2024.

#### Third Quarter 2024 Financial Results

Total revenue for the third quarter of 2024 was €57.8 million, compared to €48.0 million during the same period for 2023. The year-over-year increase in total revenue was primarily attributable to revenue contribution of €8.5 million from YORVIPATH following commercial launch in the first quarter of 2024. Non-product revenue was €2.1 million in the third quarter of 2024, compared to €1.1 million for the same period for 2023.

Total Revenue (In EUR'000s)	Three Months Septembe	Nine Months Ended September 30,		
	2024	2023	2024	2023
Revenue from external customers				
Commercial sale of products	55,710	46,968	153,598	114,414
Licenses	851	571	26,490	1,774
Other	1,272	495	9,637	12,828
Total revenue from external customers	57,833	48,034	189,725	129,016

Research and development (R&D) costs for the third quarter of 2024 were €73.5 million, compared to €111.4 million during the same period in 2023. The decline was largely tied to lower external development costs across for TransCon hGH, TransCon PTH, and TransCon CNP as well as the Eyconis spin-off.

Selling, general, and administrative (SG&A) expenses for the third quarter of 2024 were €69.8 million, compared to €63.6 million during the same period in 2023. The increase was primarily due to higher employee costs, including the impact from commercial expansion.

Total operating expenses for the third quarter of 2024 were €143.4 million compared to €175.1 million during the same period in 2023.

Net finance income for the third quarter of 2024 was  $\in$  2.9 million compared to a net finance expense of  $\in$  20.4 million during the same period in 2023. The change was primarily tied the impact of currency fluctuations.

For the third quarter of 2024, Ascendis Pharma reported a net loss of €99.2 million, or €1.72 per share (basic and diluted) compared to a net loss of €162.2 million, or €2.88 per share (basic and diluted) for the same period in 2023.

As of September 30, 2024, Ascendis Pharma had cash, cash equivalents, and marketable securities totaling €625.5 million compared to €399.4 million as of December 31, 2023. As of September 30, 2024, Ascendis Pharma had 60,642,144 ordinary shares outstanding, including 881,730 ordinary shares represented by ADSs held by the company.

#### **Conference Call and Webcast Information**

Ascendis Pharma will host a conference call and webcast today at 4:30 pm Eastern Time (ET) to discuss its third quarter 2024 financial results.

Those who would like to participate may access the live webcast <u>here</u>, or register in advance for the teleconference <u>here</u>. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at <u>https://investors.ascendispharma.com</u>. A replay of the webcast will be available on this section of the Ascendis Pharma website shortly after conclusion of the event for 30 days.

#### About Ascendis Pharma A/S

Ascendis Pharma is applying its innovative TransCon technology platform to build a leading, fully integrated biopharma company focused on making a meaningful difference in patients' lives. Guided by its core values of Patients, Science, and Passion, Ascendis uses its TransCon technologies to create new and potentially best-in-class therapies. Ascendis is headquartered in Copenhagen, Denmark and has additional facilities in Europe and the United States. Please visit <u>ascendispharma.com</u> to learn more.

#### **Forward-Looking Statements**

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Ascendis' future operations, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to (i) the U.S. launch of YORVIPATH; (ii) the timing of NDA and MAA submissions for TransCon CNP; (iii) projections for full year 2024 SKYTROFA revenue and operating expenses; (iv) the closing of the Novo Nordisk collaboration; (v) the ability of Ascendis' three endocrinology rare disease programs to address major unmet medical needs and achieve blockbuster status; (vi) Ascendis' ability to extend the success of its TransCon platform and capture significant value in the areas of metabolic and cardiovascular disease: (vii) the timing of topline results from Phase 2 New InsiGHTS Trial in Turner syndrome; (viii) the initiation of a basket trial evaluating SKYTROFA in other daily growth hormone indications; (ix) the timing by which the Ascendis Signature Access Program will begin accepting prescriptions and enrolling patients; (x) the timing of final YORVIPATH pricing in Germany; (xi) the timing of topline Week 26 data from COACH, the combination TransCon hGH and TransCon CNP trial of children with achondroplasia; (xii) Ascendis' revenues from the Novo Nordisk collaboration; (xiii) Novo Nordisk's responsibilities under the collaboration; (xiv) Ascendis' ability to apply its TransCon technology platform to build a leading, fully integrated biopharma company, and (xv) Ascendis' use of its TransCon technologies to create new and potentially best-in-class therapies. Ascendis may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Ascendis makes, including the following: dependence on third party manufacturers, distributors and service providers for Ascendis' products and product candidates; unforeseen safety or efficacy results in Ascendis' development programs or on-market products; unforeseen expenses related to commercialization of any approved Ascendis products; unforeseen expenses related to Ascendis' development programs; unforeseen selling, general and administrative expenses, other research and development expenses and Ascendis' business generally; delays in the development of its programs related to manufacturing, regulatory requirements, speed of patient recruitment or other unforeseen delays; Ascendis' ability to obtain additional funding, if needed, to support its business activities; the impact of international economic, political, legal, compliance, social and business factors. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Ascendis' business in general, see Ascendis' Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on February 7, 2024, and Ascendis' other future reports filed with, or submitted to, the SEC. Forward-looking statements do not reflect the potential impact of any future licensing, collaborations, acquisitions, mergers, dispositions, joint ventures, or investments that Ascendis may enter into or make. Ascendis does not assume any obligation to update any forwardlooking statements, except as required by law.

Ascendis, Ascendis Pharma, the Ascendis Pharma logo, the company logo, TransCon, SKYTROFA<sup>®</sup>, and YORVIPATH<sup>®</sup> are trademarks owned by the Ascendis Pharma group. © November 2024 Ascendis Pharma A/S.

**Investor Contacts:** 

Media Contact:

Scott Smith

Melinda Baker

Ascendis Pharma

ir@ascendispharma.com

Ascendis Pharma +1 (650) 709-8875 media@ascendispharma.com

## FINANCIAL TABLES FOLLOW

Ascendis Pharma A/S

## Consolidated Statements of Profit or (Loss) and Comprehensive Income / (Loss) (In EUR'000s, except share and per share data)

2024202320242023Consolidated Statement of Profit or (Loss) Revenue $57,833$ $48,034$ $189,725$ $129,016$ Cost of sales $11,201$ $7,388$ $30,235$ $24,938$ Gross profit $46,632$ $40,646$ $159,490$ $104,078$ Research and development costs $73,544$ $111,439$ $227,708$ $322,573$ Selling, general and administrative expenses $69,831$ $63,614$ $210,928$ $200,435$ Operating profit/(loss) of associate $(4,367)$ $(6,794)$ $(15,485)$ $(15,471)$ Finance expenses $25,347$ $24,519$ $70,488$ $35,640$ Profit/(loss) before tax $(98,178)$ $(161,576)$ $(335,857)$ $(339,056)$ Income taxes/(expenses) $(1,020)$ $(645)$ $(3,758)$ $(1,513)$ Net profit/(loss) for the period $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss) $(162,223)$ $(339,615)$ $(394,569)$ Net profit/(loss) for the period $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Net profit/(loss) for the period $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income $154$ $571$ <	(In EUR'000s, except share and per share data)	TI	Three Months Ended September 30,		N	Nine Months Ended September 30,			
Revenue       57,833       48,034       189,725       129,016         Cost of sales       11,201       7,388       30,235       24,938         Gross profit       46,632       40,646       159,490       104,078         Research and development costs       73,584       111,439       227,708       322,573         Selling, general and administrative expenses       69,831       63,614       210,928       200,435         Operating profit/(loss)       (96,743)       (134,407)       (279,146)       (418,930)         Share of profit/(loss) of associate       (4,367)       (6,794)       (15,485)       (15,471)         Finance income       28,279       4,142       29,262       76,985         Finance expenses       25,347       24,519       70,488       35,640         Profit/(loss) before tax       (98,178)       (161,578)       (333,657)       (333,056)         Income taxes/(expenses)       (1,020)       (162,223)       (339,615)       (394,569)         Attributable to owners of the Company       (99,198)       (162,223)       (339,615)       (394,569)         Basic and diluted earnings/(loss) per share       €       (1,72)       €       (2.88)       €       (5.33)       €       (7.02) <th></th> <th></th> <th>2024</th> <th></th> <th>2023</th> <th></th> <th>2024</th> <th></th> <th>2023</th>			2024		2023		2024		2023
Cost of sales       11,201       7,388       30,235       24,938         Gross profit       46,632       40,646       159,490       104,078         Research and development costs       73,544       111,439       227,708       322,573         Selling, general and administrative expenses       69,831       63,614       210,928       200,435         Operating profit/(loss)       (46,672)       (134,407)       (279,146)       (418,930)         Share of profit/(loss) of associate       (4,367)       (6,794)       (15,485)       (15,471)         Finance income       28,279       4,142       29,262       76,985         Finance expenses       25,347       24,519       70,488       35,640         Profit/(loss) before tax       (98,178)       (161,578)       (335,857)       (333,056)         Income taxes/(expenses)       (1,020)       (645)       (3,758)       (1,513)         Net profit/(loss) for the period       (99,198)       (162,223)       (339,615)       (394,569)         Basic and diluted earnings/(loss) per share       €       (1,72)       €       (2,88)       €       (5,93)       €       (7.02)         Number of shares used for calculation (basic and diluted)       57,535,349       56,272,698	Consolidated Statement of Profit or (Loss)								
Gross profit46,63240,646159,490104,078Research and development costs73,544111,439227,708322,573Selling, general and administrative expenses69,83163,614210,928200,435Operating profit/(loss)(96,743)(134,407)(279,146)(418,930)Share of profit/(loss) of associate(4,367)(6,794)(15,485)(15,471)Finance income28,2794,14229,26276,985Finance expenses25,34724,51970,48835,640Profit/(loss) before tax(98,178)(161,577)(335,857)(333,056)Income taxes/(expenses)(1,020)(645)(3,758)(1,513)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Basic and diluted earnings/(loss) per share€(1.72)€(2.88)€(5.93)€(7.02)Number of shares used for calculation (basic and diluted)57,535,34956,272,69857,255,76456,194,956Consolidated Statement of Comprehensive Income or (Loss)(162,223)(339,615)(394,569)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss)154571232(1,232)(1,232)Cher comprehensive income/(loss) for the period, net of tax154571232(1,232)Cher comprehensive income/(loss) for the period, net of tax(154571232(1,232)Charle comprehensive income/(loss) for the per	Revenue		57,833		48,034		189,725		129,016
Research and development costs73,544111,439227,708322,573Selling, general and administrative expenses69,83163,614210,928200,435Operating profit/(loss)(96,743)(134,407)(279,146)(418,930)Share of profit/(loss) of associate(4,367)(6,794)(15,485)(15,471)Finance income28,2794,14229,26276,985Finance expenses25,34724,51970,48835,640Profit/(loss) before tax(98,178)(161,578)(335,857)(339,056)Income taxes/(expenses)(1,020)(645)(3,758)(1,513)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company(91,129)€(1,72)€(2,88)€(7.02)Number of shares used for calculation (basic and diluted)57,535,34956,272,69857,255,76456,194,956Number of shares used for calculation (basic and diluted)(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Other comprehensive income/(loss) for the period, net of tax(99,044)(161,652)(339,383)(395,801)	Cost of sales		11,201		7,388		30,235		24,938
Selling, general and administrative expenses $69,831$ $63,614$ $210,928$ $200,435$ Operating profit/(loss)(loss) of associate(loss)	Gross profit		46,632		40,646		159,490		104,078
Operating profit/(loss)(96,743)(134,407)(279,146)(418,930)Share of profit/(loss) of associate $(4,367)$ $(6,794)$ $(15,485)$ $(15,471)$ Finance income $28,279$ $4,142$ $29,262$ $76,985$ Finance expenses $25,347$ $24,519$ $70,488$ $35,640$ Profit/(loss) before tax(98,178)(161,578)(335,857)(393,056)Income taxes/(expenses) $(1,020)$ $(645)$ $(3,758)$ $(1,513)$ Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss)(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss): $57,535,349$ $57,71$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net $154$ $571$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net $(99,044)$ $(161,652)$ $(339,383)$ $(395,801)$	Research and development costs		73,544		111,439		227,708		322,573
Share of profit/(loss) of associate(1,367)(6,794)(15,485)(15,471)Finance income $28,279$ $4,142$ $29,262$ $76,985$ Finance expenses $25,347$ $24,519$ $70,488$ $35,640$ Profit/(loss) before tax(98,178)(161,578)(333,657)(333,056)Income taxes/(expenses) $(1,020)$ (645) $(3,758)$ $(1,513)$ Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Basic and diluted earnings/(loss) per share $(1,172) \in (1,72) \in (2,88) \in (5,93) \in (7,02)$ $(7,02)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss): $154$ $571$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net of tax $154$ $571$ $232$ $(1,232)$ Total comprehensive income/(loss) for the period, net of tax $(99,044)$ $(161,652)$ $(339,383)$ $(395,801)$	Selling, general and administrative expenses		69,831		63,614		210,928		200,435
Finance income $28,279$ $4,142$ $29,262$ $76,985$ Finance expenses $25,347$ $24,519$ $70,488$ $35,640$ Profit/(loss) before tax(98,178)(161,578)(335,857)(393,056)Income taxes/(expenses) $(1,020)$ $(645)$ $(3,758)$ $(1,513)$ Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Basic and diluted earnings/(loss) per share $\in$ $(1.72)$ $\in$ $(2.88)$ $\in$ $(5.93)$ $\in$ $(7.02)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss)(162,223)(339,615)(394,569)Net profit/(loss) for the period(99,198)(162,223) $(339,615)$ $(394,569)$ Items that may be reclassified subsequently to profit or (loss): $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Exchange differences on translating foreign operations $154$ $571$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net of tax $154$ $571$ $232$ $(1,232)$ Total comprehensive income/(loss) for the period, net of tax $(99,044)$ $(161,652)$ $(339,383)$ $(395,801)$	Operating profit/(loss)		(96,743)		(134,407)		(279,146)		(418,930)
Finance expenses $25,347$ $24,519$ $70,488$ $35,640$ Profit/(loss) before tax(98,178)(161,578)(335,857)(393,056)Income taxes/(expenses)(1,020)(645)(3,758)(1,513)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company(99,198)(162,223)(339,615)(394,569)Basic and diluted earnings/(loss) per share $\in$ (1,72) $\in$ (2.88) $\in$ (5.93) $\in$ (7.02)Number of shares used for calculation (basic and diluted)57,535,34956,272,69857,255,76456,194,956Consolidated Statement of Comprehensive Income or (Loss)(162,223)(339,615)(394,569)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):Exchange differences on translating foreign operations154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(99,044)(161,652)(339,383)(395,801)	Share of profit/(loss) of associate		(4,367)		(6,794)		(15,485)		(15,471)
Profit/(loss) before tax(98,178)(161,578)(335,857)(393,056)Income taxes/(expenses) $(1,020)$ $(645)$ $(3,758)$ $(1,513)$ Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Basic and diluted earnings/(loss) per share $\in$ $(1.72)$ $\in$ $(2.88)$ $\in$ $(5.93)$ $\in$ $(7.02)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss)Net profit/(loss) for the period (loss):Exchange differences on translating foreign operations $0154$ $571$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net of tax $154$ $571$ $232$ $(1,232)$ Total comprehensive income/(loss) for the period, net of tax $(99,044)$ $(161,652)$ $(339,383)$ $(395,801)$	Finance income		28,279		4,142		29,262		76,985
Income taxes/(expenses) $(1,020)$ $(645)$ $(3,758)$ $(1,513)$ Net profit/(loss) for the period $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Attributable to owners of the Company Basic and diluted earnings/(loss) per share $\in$ $(1,72)$ $\in$ $(2.88)$ $\in$ $(5.93)$ $\in$ $(7.02)$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss) $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Net profit/(loss) for the period (loss): $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Consolidated Statement of Comprehensive Income or (Loss) $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Net profit/(loss) for the period (loss): $(99,198)$ $(162,223)$ $(339,615)$ $(394,569)$ Consolidated Statement of Comprehensive Income or (Loss) $(154)$ $5711$ $232$ $(1,232)$ Other comprehensive income/(loss) for the period, net of tax $154$ $5711$ $232$ $(1,232)$ Total comprehensive income/(loss) for the period, net of tax $(99,044)$ $(161,652)$ $(339,383)$ $(395,801)$	Finance expenses		25,347		24,519		70,488		35,640
Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Attributable to owners of the Company(99,198)(162,223)(339,615)(394,569)Basic and diluted earnings/(loss) per share $\in$ (1.72) $\in$ (2.88) $\in$ (5.93) $\in$ (7.02)Number of shares used for calculation (basic and diluted)57,535,34956,272,69857,255,76456,194,956Consolidated Statement of Comprehensive Income or (Loss)(162,223)(339,615)(394,569)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):Exchange differences on translating foreign operations154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)(1,232)Total comprehensive income/(loss) for the period, net of tax(99,044)(161,652)(339,383)(395,801)	Profit/(loss) before tax		(98,178)		(161,578)		(335,857)		(393,056)
Attributable to owners of the Company Basic and diluted earnings/(loss) per share $(99,198)$ $\in$ $(162,223)$ $\in$ $(339,615)$ $\in$ $(394,569)$ $\in$ Number of shares used for calculation (basic and diluted) $57,535,349$ $56,272,698$ $57,255,764$ $56,194,956$ Consolidated Statement of Comprehensive Income or (Loss) $(99,198)$ $1tems that may be reclassified subsequently to profit or(loss):(162,223)154(339,615)56,272,698(339,615)57,255,764(394,569)56,194,956Consolidated Statement of Comprehensive Incomeor (Loss)(99,198)1tems that may be reclassified subsequently to profit or(loss):(162,223)154(339,615)57,255,764(394,569)162,223)Definition(99,198)154(162,223)57,1(339,615)232(1,232)(1,232)(1,232)Other comprehensive income/(loss) for the period,net of tax15499,044571232(161,652)232, (1,232)(339,383)Total comprehensive income/(loss) for the period,of tax(99,044)(161,652)(339,383)(395,801)$	Income taxes/(expenses)		(1,020)		(645)		(3,758)		(1,513)
Basic and diluted earnings/(loss) per share Number of shares used for calculation (basic and diluted)	Net profit/(loss) for the period		(99,198)		(162,223)		(339,615)		(394,569)
Number of shares used for calculation (basic and diluted)57,535,34956,272,69857,255,76456,194,956Consolidated Statement of Comprehensive Income or (Loss)(99,198)(162,223)(339,615)(394,569)Net profit/(loss) for the period (loss):(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(199,044)(161,652)(339,383)(395,801)	Attributable to owners of the Company		(99,198)		(162,223)		(339,615)		(394,569)
Consolidated Statement of Comprehensive Income or (Loss)(99,198)(162,223)(339,615)(394,569)Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):154571232(1,232)Exchange differences on translating foreign operations154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(99,044)(161,652)(339,383)(395,801)	Basic and diluted earnings/(loss) per share	€	(1.72)	€	(2.88)	€	(5.93)	€	(7.02)
or (Loss) Net profit/(loss) for the period (99,198) (162,223) (339,615) (394,569) Items that may be reclassified subsequently to profit or (loss): Exchange differences on translating foreign operations 154 571 232 (1,232) Other comprehensive income/(loss) for the period, net of tax 154 571 232 (1,232) Total comprehensive income/(loss) for the period, net of tax (99,044) (161,652) (339,383) (395,801)	Number of shares used for calculation (basic and diluted)		57,535,349		56,272,698		57,255,764		56,194,956
Net profit/(loss) for the period(99,198)(162,223)(339,615)(394,569)Items that may be reclassified subsequently to profit or (loss):154571232(1,232)Exchange differences on translating foreign operations154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(199,044)(161,652)(339,383)(395,801)	•								
(loss):154571232(1,232)Exchange differences on translating foreign operations154571232(1,232)Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(199,044)(161,652)(339,383)(395,801)	Net profit/(loss) for the period		(99,198)		(162,223)		(339,615)		(394,569)
Other comprehensive income/(loss) for the period, net of tax154571232(1,232)Total comprehensive income/(loss) for the period, net of tax(99,044)(161,652)(339,383)(395,801)									
net of tax         154         571         232         (1,232)           Total comprehensive income/(loss) for the period, net of tax         (199,044)         (161,652)         (339,383)         (395,801)	Exchange differences on translating foreign operations		154		571		232		(1,232)
of tax (99,044) (161,652) (339,383) (395,801)			154		571		232		(1,232)
Attributable to owners of the Company         (99,044)         (161,652)         (339,383)         (395,801)			(99,044)		(161,652)		(339,383)		(395,801)
	Attributable to owners of the Company		(99,044)		(161,652)		(339,383)		(395,801)

### Ascendis Pharma A/S

Consolidated Statements of Financial Position (In EUR'000s)

Assets		
Non-current assets		
Intangible assets	4,106	4,419
Property, plant and equipment	97,522	110,634
Investment in associates	16,213	5,686
Other receivables	2,202	2,127

September 30, 2024

December 31, 2023

Current assets         265,433         206,831           Inventories         265,433         208,831           Income tax receivables         1,995         602           Other receivables         15,259         19,097           Prepayments         32,440         38,578           Marketable securities         -         7,275           Cash and cash equivalents         625,515         332,164           973,740         702,721         1,093,783         825,587           Equity and liabilities         1,093,783         825,587           Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (07,320)         (145,697)           Non-current liabilities         5,000         5,449           Borrowings         338,930         222,996           Contract liabilities         5,000         5,449           Deferred tax liabilities         5,030         5,449           Deferred tax liabilities         500,410         550,391           Current liabilities         1,68,46         143,226           Contract liabilities         1,586         1,184           Trade payables and accrued expenses </th <th></th> <th>120,043</th> <th>122,866</th>		120,043	122,866
Trade receivables         33,098         35,374           Income tax receivables         1,995         802           Other receivables         15,259         19,097           Prepayments         32,440         38,578           Marketable securities         -         7,275           Cash and cash equivalents         625,515         392,164           973,740         702,721         702,721           Total assets         1,093,783         825,587           Equity and liabilities         8,143         7,749           Share capital         8,143         7,749           Total assets         (105,463)         (153,446)           Total equity         (105,463)         (153,446)           Total equity         (105,463)         (145,697)           Non-current liabilities         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         5,000         5,949           Deferred tax liabilities         50,001         50,949           Dertwritive liabilities         168,346         143,296           Dorrowings         22,064         407,095           Derteruent liabilities         1,586         1,184	Current assets		
Income tax receivables         1,995         802           Other receivables         15,259         19,097           Prepayments         32,440         38,578           Marketable securities         -         7,275           Cash and cash equivalents         625,515         392,164           973,740         702,721         Total assets         1,093,783         825,587           Equity and liabilities         1,093,783         825,587         1,093,783         825,587           Share capital         8,143         7,749         102,721         103,463         (15,3466)         (15,3463)         (15,3463)         (15,3466)         (15,3463)         (15,3466)         (15,3463)         (15,3466)         (145,697)         (14,5697)	Inventories	265,433	208,931
Other receivables         15,259         19,097           Prepayments         32,440         38,578           Marketable securities         -         7,275           Cash and cash equivalents         625,515         392,164           973,740         702,721           Total assets         1093,783         825,587           Equity and liabilities         8,143         7,749           Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (105,463)         (153,446)           Total equity         (105,463)         (153,446)           Non-current liabilities         8,030         22,996           Contract liabilities         5,000         5,549           Deferred tax liabilities         338,930         22,996           Cornert liabilities         352,646         234,775           Current liabilities         590,410         550,941           Derivative liabilities         10,958         14,226           Derivative liabilities         1,566         1,144           Total equyables and accrued expenses         75,268         94,566           Other current liabilities         1,566	Trade receivables	33,098	35,874
Prepayments         32,440         38,578           Marketable securities         -         7,275           Cash and cash equivalents         625,515         939,740           973,740         972,721           Total assets         1,093,783         825,587           Equity and liabilities         8,143         7,749           Equity         (105,463)         (153,446)           Otat equity         (105,463)         (153,446)           Total equity         (197,320)         (145,697)           Non-current liabilities         8,716         5,300           Borrowings         338,930         222,996           Contract liabilities         8,716         5,330           Deferred tax liabilities         8,716         5,949           Convertible notes, matures in April 2028         352,646         234,775           Current liabilities         168,346         143,296           Derivative liabilities         590,410         550,94,10           Other current liabilities         1,568         1,141           Convertible notes, matures in April 2028         19,0410         550,94,10           Derivative liabilities         1,568         1,141           Income tax payables         34	Income tax receivables	1,995	802
Marketable securities         -         7,275           Cash and cash equivalents         625,515         392,164           Total assets         973,740         702,721           Total assets         1,093,783         825,587           Equity and liabilities         8,143         7,749           Equity         (105,463)         (153,446)           Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (105,463)         (153,446)           Non-current liabilities         5,000         5,949           Deferred tax liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Convertible notes, matures in April 2028         350,9410         550,391           Derivative liabilities         163,346         143,226           Other current liabilities         1,586         1,184           Trade ayables and accrued expenses         75,268         94,566           Other liabilities         1,016         2,299           Provisions         1,016         2,296           Other current liabilities         1,583,61         143,296           Derivativ	Other receivables	15,259	19,097
Cash and cash equivalents         625,515 973,740         392,164 7702,721           Total assets         1,093,783         825,587           Equity and liabilities         1,093,783         825,587           Equity and liabilities         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (105,463)         (145,697)           Non-current liabilities         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Current liabilities         352,646         234,775           Current liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         1,566         1,184           Trade payables and accrued expenses         75,268         94,566           Other current liabilities         1,266         1,184           Trade payables         1,016         2,299           Provisions         1,016         2,299	Prepayments	32,440	
973,740         702,721           Total assets         1,093,783         825,587           Equity and liabilities         8,143         7,749           Distributable equity         (105,463)         (153,446)           Otal equity         (105,463)         (145,697)           Non-current liabilities         9         9           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Convertible notes, matures in April 2028         352,646         234,775           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Other current liabilities         590,410         550,391           Other current liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other current liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,288         32,719           Other liabilities         1,586         1,184           Trade gayables and accrued expenses	Marketable securities	_	7,275
Total assets         1,093,783         825,587           Equity and liabilities         8,143         7,749           Equity         (105,463)         (153,446)           Distributable equity         (105,463)         (153,446)           Total equity         (105,463)         (145,697)           Non-current liabilities         (97,320)         (145,697)           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Convertible notes, matures in April 2028         352,646         234,775           Current liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         1586         1,184           Contract liabilities         1,586         1,184           Drade payables and accrued expenses         75,268         94,566           Other current liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         1,016         2,299           Total liabilities         1,016         2,299           Total liabil	Cash and cash equivalents	625,515	392,164
Equity and liabilities           Equity           Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (97,320)         (145,697)           Non-current liabilities         338,930         222,996           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         352,646         234,775           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028         352,646         407,095           Derivative liabilities         168,346         143,296           Dorrowings         422,064         407,095           Derivative liabilities         590,410         550,391           Other current liabilities         590,410         550,391           Drivature liabilities         1,586         1,184           Borrowings         27,668         14,174           Contract liabilities         1,286         1,184           Provisions         75,268         94,566           Other liabilities         1,016         2,299           Provisions         1,016<		973,740	702,721
Equity           Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (105,463)         (153,446)           Total equity         (97,320)         (145,697)           Non-current liabilities         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Observent liabilities         8,716         5,830           Convertible notes, matures in April 2028         352,646         234,775           Current liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         27,668         14,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         1,248,047         186,118           Income tax payables         1,016         2,299           Provisions         248,047         186,118           838,457         736,509         11,91,103         971,284 <td>Total assets</td> <td>1,093,783</td> <td>825,587</td>	Total assets	1,093,783	825,587
Share capital         8,143         7,749           Distributable equity         (105,463)         (153,446)           Total equity         (97,320)         (145,697)           Non-current liabilities         (97,320)         (145,697)           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Convertible notes, matures in April 2028         352,646         234,775           Current liabilities         352,646         234,775           Derivative liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           Derivative liabilities         1580,410         550,391           Other current liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         1,016         2,299           Provisions         1,016         2,299           Total liabilities         1,016         2,299           Provisions	Equity and liabilities		
Distributable equity         (105,463)         (153,446)           Total equity         (97,320)         (145,697)           Non-current liabilities         (97,320)         (145,697)           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Current liabilities         8,716         5,830           Convertible notes, matures in April 2028         Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296         590,410         550,391           Other current liabilities         27,668         14,174         500,310         550,391           Other liabilities         1,586         1,184         75,268         94,566           Other liabilities         1,586         1,184         76,268         94,566           Other liabilities         42,241         41,176         2,298           Provisions         27,668         14,174         2,299           Other liabilities         1,016         2,299           Other spables         2,214         41,176           Income tax payables         1,016         2,299 <td>Equity</td> <td></td> <td></td>	Equity		
Total equity         (97,320)         (145,697)           Non-current liabilities         338,930         222,996           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Current liabilities         352,646         234,775           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028         422,064         407,095           Derivative liabilities         168,346         143,296           Derivative liabilities         590,410         550,391           Other current liabilities         590,410         550,391           Derivative liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         1,586         1,184           Income tax payables         1,016         2,299           Provisions         100,268         32,719           Provisions         1,911,103         971,284	Share capital	8,143	7,749
Non-current liabilities         338,930         222,996           Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Current liabilities         332,646         234,775           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028         422,064         407,095           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Borrowings         27,668         144,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         1,016         2,299           Provisions         1,016         2,299           Provisions         100,268         32,719           Total liabilities         1,191,103         971,284	Distributable equity	(105,463)	(153,446)
Borrowings         338,930         222,996           Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           Current liabilities         352,646         234,775           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028	Total equity	(97,320)	(145,697)
Contract liabilities         5,000         5,949           Deferred tax liabilities         8,716         5,830           352,646         234,775           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028         7         7           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Derivative liabilities         590,410         550,391           Other current liabilities         590,410         550,391           Contract liabilities         1,586         1,41,74           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         838,457         736,509           Total liabilities         1,191,103         971,284	Non-current liabilities		
Deferred tax liabilities         8,716         5,830           Current liabilities         352,646         234,775           Convertible notes, matures in April 2028         2         3         2         3 <td>Borrowings</td> <td>338,930</td> <td>222,996</td>	Borrowings	338,930	222,996
352,646         234,775           Current liabilities         Convertible notes, matures in April 2028           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Sonowings         422,064         407,095           Derivative liabilities         168,346         143,296           Sonowings         27,668         143,296           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         838,457           Total liabilities         1,191,103         971,284	Contract liabilities	5,000	5,949
Current liabilities         Convertible notes, matures in April 2028           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Sorrowings         168,346         143,296           Derivative liabilities         168,346         143,296           Borrowings         27,668         14,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         32,719           Cotal liabilities         1,191,103         971,284	Deferred tax liabilities	8,716	5,830
Convertible notes, matures in April 2028           Borrowings         422,064         407,095           Derivative liabilities         168,346         143,296           Derivative liabilities         168,346         143,296           State         590,410         550,391           Other current liabilities         590,410         550,391           Borrowings         27,668         14,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         32,719           Total liabilities         1,191,103         971,284		352,646	234,775
Borrowings       422,064       407,095         Derivative liabilities       168,346       143,296         590,410       550,391         Other current liabilities       590,410       550,391         Borrowings       27,668       14,174         Contract liabilities       1,586       1,184         Trade payables and accrued expenses       75,268       94,566         Other liabilities       42,241       41,176         Income tax payables       1,016       2,299         Provisions       100,268       32,719         248,047       186,118       838,457         Total liabilities       1,191,103       971,284	Current liabilities		
Derivative liabilities         168,346         143,296           590,410         550,391           Other current liabilities         27,668         14,174           Borrowings         27,668         14,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         186,118           Total liabilities         1,191,103         971,284	Convertible notes, matures in April 2028		
Other current liabilities         590,410         550,391           Borrowings         27,668         14,174           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         838,457           Total liabilities         1,191,103         971,284		422,064	407,095
Other current liabilities         27,668         14,174           Borrowings         1,586         1,184           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         838,457           Total liabilities         1,191,103         971,284	Derivative liabilities	168,346	143,296
Other current liabilities         27,668         14,174           Borrowings         1,586         1,184           Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118         838,457           Total liabilities         1,191,103         971,284		590,410	550,391
Contract liabilities         1,586         1,184           Trade payables and accrued expenses         75,268         94,566           Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118           838,457         736,509           Total liabilities         1,191,103         971,284	Other current liabilities		
Trade payables and accrued expenses       75,268       94,566         Other liabilities       42,241       41,176         Income tax payables       1,016       2,299         Provisions       100,268       32,719         248,047       186,118         838,457       736,509         Total liabilities       1,191,103       971,284	Borrowings	27,668	14,174
Other liabilities         42,241         41,176           Income tax payables         1,016         2,299           Provisions         100,268         32,719           248,047         186,118           838,457         736,509           Total liabilities         1,191,103         971,284	Contract liabilities	1,586	1,184
Income tax payables       1,016       2,299         Provisions       100,268       32,719         248,047       186,118         838,457       736,509         Total liabilities       1,191,103       971,284	Trade payables and accrued expenses	75,268	94,566
Provisions         100,268         32,719           248,047         186,118           838,457         736,509           1,191,103         971,284		42,241	41,176
248,047         186,118           838,457         736,509           1,191,103         971,284	Income tax payables	1,016	2,299
838,457         736,509           Total liabilities         1,191,103         971,284	Provisions	100,268	32,719
838,457         736,509           Total liabilities         1,191,103         971,284		248,047	186,118
Total liabilities         1,191,103         971,284		838,457	
	Total liabilities	· · · · · · · · · · · · · · · · · · ·	
			· · · · · ·



Source: Ascendis Pharma